HD-6277 explained

HD-6277 is a selective g-protein-coupled receptor 40 agonist developed by Hyundai Pharmaceutical to treat diabetes.[1] [2]

Notes and References

  1. Kim . Daehoon . Kim . Chun Hwa . Choi . Hyo Sun . Yang . Goeun . Kang . Seung Jun . Lee . Sun Hee . Lim . Kwan Soo . Park . Min Ah . Kim . Doo Young . Rhee . Jae Keol . HD-6277, a Novel GPR40 Agonist, Improves Glucose Homeostasis and Enhanced Glucose-Dependent Insulin Secretion in Beta Cells and Type 2 Diabetic Rats . Diabetes . 1 July 2018 . 67 . Supplement_1 . 10.2337/db18-1202-P. 91116872 .
  2. Kim . Ki-Hwan . Kim . Pan-Kyung . Yang . Hye-Jung . 1179-P: Pharmacokinetics, Pharmacodynamics, and Safety of HD-6277, a Selective Agonist of G-Protein-Coupled Receptor 40, in Healthy Subjects as a First-in-Human Study . Diabetes . 1 June 2019 . 68 . Supplement_1 . 10.2337/db19-1179-P. 195427023 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "HD-6277".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.